NCT05113849View on ClinicalTrials.gov

Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

IN-B009 (Low-dose)

Two doses, intramuscular injection

BIOLOGICAL

IN-B009 (High-dose)

Two doses, intramuscular injection

Trial Locations (3)

Unknown

RECRUITING

Chungbuk National University Hospital, Chungju

RECRUITING

Jeonbuk National University Hospital, Jeonju

RECRUITING

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY